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Aim: With the purpose of delivering high doses of glabrescione B (GlaB) to solid 
tumors after systemic administration, long-circulating GlaB-loaded oil-cored 
polymeric nanocapsules (NC-GlaB) were formulated. Materials & methods: Synthesis 
of GlaB and its encapsulation in nanocapsules (NCs) was performed. Empty and GlaB-
loaded NCs were assessed for their physico-chemical properties, in vitro cytotoxicity 
and in vivo biodistribution. Results: GlaB was efficiently loaded into NCs (~90%), 
which were small (~160 nm), homogeneous and stable upon storage. Further, GlaB 
and NC-GlaB demonstrated specific activities against the cancer stem cells. Preliminary 
studies in tumor-bearing mice supported the ability of NC to accumulate in pancreatic 
tumors. Conclusion: This study provides early evidence that NC-GlaB has the potential 
to be utilized in a preclinical setting and justifies the need to perform therapeutic 
experiments in mice.
First draft submitted: 7 November 2016; Accepted for publication: 26 January 2017; 
Published online: 21 March 2017
Keywords:  glabrescione B (GlaB) • Hedgehog (Hh) pathway • oil-cored polymeric 
 nanocapsules
Cancer stem cells (CSCs) represent a sub-
population of stem cells within a tumor 
which drive growth and metastasis. While 
chemotherapy and radiation therapy are fre-
quently able to eradicate most of the tumor 
bulk and proliferative cells, these treatments 
frequently fail in eradicating the quiescent 
CSCs, which might be dormant for years [1]. 
Eradication of the CSCs is thought to be 
essential to achieve complete tumor ablation 
and prevent cancer relapse [2]. Several signal-
ing pathways that regulate normal stem cell 
self-renewal cause neoplastic proliferation 
when dysregulated by mutations [3]. Among 
those is the Hedgehog (Hh) signaling path-
way, which is essential for tissue develop-
ment and stemness, and whose dysregulation 
leads to tumorigenesis [4]. Aberrant activa-
tion of the Hh pathway is responsible for 
the tumorigenesis of several human cancers 
including medulloblastoma (MB) [5], rhab-
domyosarcoma [6,7], melanoma [8], basal cell 
carcinoma (BCC) [9], breast [10], liver [11], 
lung [12,13], prostate [14,15], brain and pancreas 
tumors [16–19]. Thus, this pathway has been 
widely targeted in recent years for the devel-
opment of anticancer drugs. A recent study 
from the co-authors of this paper identified 
glabrescione B (GlaB) [20], a naturally occur-
ring isoflavone in Derris glabrescens [21], as the 
first small molecule that binds the Hh modu-
lator Gli1 (a zinc finger) and impairs its activ-
ity by interfering with Gli–DNA interaction. 
GlaB was shown to inhibit the in vitro and in 
vivo growths of multiple Hh-dependent can-
cer cells and CSCs, as well as the self-renewal 
ability and clonogenicity of tumor-derived 
stem cells [22]. In this previously reported 
study, the ability of GlaB against MB in the 
allograft model of MB cells by subcutane-
ous injection, using a solution of GlaB (75 
μmol/kg) prepared in 2-hydroxypropyl-β-
Polymeric glabrescione B nanocapsules for 
passive targeting of Hedgehog-dependent 
tumor therapy in vitro
Cinzia Ingallina1,2, Pedro M 
Costa1, Francesca Ghirga3, 
Rebecca Klippstein1, Julie T 
Wang1, Simone Berardozzi2,3, 
Naomi Hodgins1, Paola 
Infante3, Steven M Pollard4, 
Bruno Botta*,2 & Khuloud T 
Al-Jamal**,1
1Institute of Pharmaceutical Science, 
Faculty of Life Sciences & Medicine, 
King’s College London, Franklin−Wilkins 
Building, London, SE1 9NH, UK 
2Dipartimento di Chimica e Tecnologie 
del Farmaco, Sapienza Università di 
Roma, Rome, Italy 
3Center for Life NanoScience@Sapienza, 
Istituto Italiano di Tecnologia, Rome, Italy 
4MRC Centre for Regenerative Medicine, 
University of Edinburgh, Edinburgh 
bioQuarter, 5 Little France Drive, 
Edinburgh EH16 4UU, UK 
*Author for correspondence: 
Tel.: +39 064 991 2781 
Fax: +39 06 49693323 
bruno.botta@uniroma1.it 
**Author for correspondence:  
Tel.: +44 207 848 4525 
khuloud.al-jamal@kcl.ac.uk
For reprint orders, please contact: reprints@futuremedicine.com
712 Nanomedicine (Lond.) (2017) 12(7) future science group
Research Article    Al-Jamal, Botta, Ingallina et al.
cyclodextrin:ethanol (3:1), was assessed. During the 
18-day treatment, GlaB significantly suppressed the 
tumor mass compared with the control. Despite the 
promising findings confirming the therapeutic efficacy 
of GlaB against Hh-dependent cancer, it was con-
cluded that delivery approaches are required to solubi-
lize GlaB in aqueous solvents so that systemic adminis-
tration of relatively high doses is feasible.
Nanotechnology-based drug delivery systems offer 
the possibility of solubilizing poorly soluble drugs, 
protecting labile molecules and improving on tissue 
biodistribution [23]. Among the different drug deliv-
ery technologies, polymeric nanocapsules (NCs) have 
attracted growing attention due to the high loading 
capacity of hydrophobic molecules, as well as long-
term stability, offering enhanced bioavailability of the 
active compound [24,25]. NCs consist of a core-shell 
structure made of hydrophilic polymer stabilized with 
lipophilic and/or hydrophilic surfactants surround-
ing an oily core, in which active molecules are con-
fined [26]. Their preparation is generally cheap, fast 
and easily scalable.
This work focused on developing GlaB-loaded oil-
cored polymeric NCs to improve its water solubility, so 
that it targets Hh-dependent cancer cells in vitro and 
in vivo. The choice of this formulation was encouraged 
by our previous studies for the delivery of water-insol-
uble drugs such as quercetin [27] and curcumin [28]. 
Physico-chemical properties, including hydrodynamic 
diameter, polydispersity index (PDI), ζ potential and 
stability, were determined. Once the desired formula-
tion was identified, the anticancer activity of both GlaB 
and NC-GlaB was evaluated in vitro against a range 
of CSCs and non-CSCs, which have been reported to 
have a strong dependence on the Hh pathway. Finally, 
the in vivo biodistribution profile and organ histology 
of intravenously administered NC-GlaB was assessed 
in pancreatic-tumor-bearing mice. Overall, this study 
provides early evidence that NC-GlaB has the poten-
tial to be utilized in a preclinical setting, aiming at its 
future use in clinic.
Materials & methods
Materials
SnakeSkin™ (10K molecular weight cut-off [MWCO] 
dialysis tubing) was acquired from ThermoFisher (CA, 
USA); soybean lecithin (Epikuron 140 V) was a kind 
donation from Cargill Pharmaceuticals (MN, USA). 
Castor oil, Tween® 80, methylene chloride, absolute 
ethanol, DMSO and acetone were acquired from 
Sigma-Aldrich (UK). Bovine serum albumin solution 
7.5% and 50 mM β-mercaptoethanol were purchased 
from ThermoFisher Scientific (UK). 75/25 DL-lactide/
glycolide conjugate (PLGA–COOH, M
w
 ≈ 18,000) 
was a gift from Purac Biomaterials (The Netherlands). 
PLGA–NH–PEG and PLGA–NH–PEG–NH–DTPA 
were synthesized as we previously described [27,28]. The 
radioactivity tracer [111In]Cl
3
 (aqueous solution) was 
obtained from Convidien UK Commercial LTD (UK) 
and was used without prior purification. TLC strips for 
radiolabeling were acquired from Agilent Technologies 
UK Ltd (UK) and flow cytometry tubes were obtained 
from VWR (UK).
Synthesis of GlaB
2′-hydroxy-4′,6′-dimethoxyacetophenone 1
A flame-dried flask was charged with 2′,4′,6′-trime-
thoxyacetophenone (5 g, 23.8 mmol; Sigma-Aldrich 
630594) and dry CH
2
Cl
2
 (75 ml) under argon. BBr
3
 
(15 ml, 87.3 mmol) was added drop wise. The resulting 
solution was stirred at room temperature for 2 h before 
adding 4 M NaOH (90 ml) and allowed to stand 
for 30 min. The solution was extracted with CH
2
Cl
2
 
and combined organic layers were washed with brine, 
dried over Na
2
SO
4
 and finally concentrated under 
reduced pressure. The resulting solid was recrystallized 
from EtOH and white crystals of 2′-hydroxy-4′,6′-
dimethoxyacetophenone 1 (4.43 g) were obtained.
White solid (yield 98%); melting point (mp) 
81–82°C; 1H NMR (400 MHz, acetone-d
6
, δ): 13.8 
(s, 1H, OH), 5.94 (d, J = 2.4 Hz, 1H, Ar H), 5.91 (d, 
J = 2.4 Hz, 1H, Ar H), 3.80 (s, 3H, OCH
3
), 3.72 (s, 
3H, OCH
3
), 2.43 (s, 3H, CH
3
); 13C NMR (100 MHz, 
acetone-d
6
, δ): 202.5 (C=O), 167.36 (C4), 166.34 
(C6), 163.15 (C2), 105.5 (C1), 93.42 (C3), 90.43 
(C5), 55.20 (OCH
3
), 55.00 (OCH
3
), 31.94 (CH
3
); IR 
(KBr): ν = 3100, 1614, 1271 cm-1; high-resolution mass 
spectrometry (HRMS; ESI) m/z: [M+H]+ calculated 
for C
10
H
12
O
4
+H+, 197.080800; found, 197.080848.
3-dimethylamino-1-(2-hydroxy-4,6-
dimethoxyphenyl) propenone 2
A mixture of 2′-hydroxy-4′,6′-dimethoxyacetophenone 
1 (4.5 g, 22.9 mmol) and N,N-dimethylformamide 
dimethylacetal (13 ml, 97.1 mmol) was heated at 95°C 
for 3 h. Afterward, the solvent was removed under 
reduced pressure and the obtained 2 (5.8 g) was used in 
the subsequent step without any further  purification.
Red solid (quantitative yield); mp 145–147°C; 1H 
NMR (400 MHz, CDCl
3
, δ): 15.65 (s, 1H, OH), 7.92 
(d, J = 12 Hz, 1H, =CH–N), 6.25 (d, J = 12.0 Hz, 1H, 
=CH–(CO), 6.07 (d, J = 2.4 Hz, 1H, Ar H), 5.91 (d, J 
= 2.4 Hz, 1H, Ar H), 3.84 (s, 3H, OCH
3
), 3.80 (s, 3H, 
OCH
3
), 3.15 (s, 3H, NCH
3
), 2.92 (s, 3H, NCH
3
); 13C 
NMR (100 MHz, CDCl
3
, δ): 191.64 (C=O), 169.00 
(C4), 165.54 (C6), 162.86 (C2), 155.83 (CH–N), 
106.58 (C1), 96.27 (CH–(CO)), 95.59 (C3), 92.06 
(C5), 57.09 (OCH
3
), 56.57 (OCH
3
); IR (KBr): ν = 
www.futuremedicine.com 713future science group
Polymeric glabrescione B nanocapsules for tumor therapy in vitro    Research Article
3447, 1614, 1542, 1362 cm-1; ESI–MS m/z: [M+H]+ 
calculated for C
13
H
17
O
4
N+H+, 252.1; found, 252.3.
3-iodo-5,7-dimethoxy-4H-chromen-4-one 3
The enamino ketone 2 was dissolved in CH
3
OH (450 
ml) and I
2
 (11.7 g, 46.2 mmol) was added to the solu-
tion. The mixture was stirred at room temperature 
for 1 h, then the solvent was evaporated. To remove 
residual I
2
, the crude was treated with a saturated aque-
ous Na
2
S
2
O
3
 solution until the mixture became clear. 
The mixture was then extracted with CHCl
3
, and 
the combined organic layers were dried over Na
2
SO
4
 
and concentrated under reduced pressure. The residue 
was purified by column chromatography using hex-
ane–EtOAc as eluent to obtain 3-iodo-5,7-dimethoxy-
4H-chromen-4-one 3 (2.5 g) as a white powder.
White solid (yield 33%); mp 156–157°C; 1H NMR 
(400 MHz, CDCl
3
, δ): 8.02 (s, 1H, H-2), 6.37 (d, J 
= 2.0 Hz, 1H, Ar H), 6.32 (d, J = 2.0 Hz, 1H, Ar H), 
3.87 (s, 3H, OCH
3
), 3.82 (s, 3H, OCH
3
); 13C NMR 
(100 MHz, CDCl
3
, δ): 183.43 (C=O), 164.28 (C7), 
160.97 (C5), 159.81 (C9), 155.33 (C2), 107.53 (C10), 
96.59 (C8), 92.44 (C6), 89.71 (=C–I), 56.41 (OCH
3
), 
55.79 (OCH
3
); IR (KBr): ν = 1671, 1640, 1600–1450 
cm-1; HRMS (ESI) m/z: [M+H]+ calculated for 
C
11
H
9
O
4
I+H+, 332.961800; found, 332.961633.
3-(3′,4′-methylendioxyphenyl)-5,7-dimethoxy-4H-
chromen-4-one 4
To a solution of 3 (2.5 g, 7.5 mmol), in 1,2-dimethoxy-
ethane/H
2
O = 50:50 (150 ml) were added Na
2
CO
3
 
(3.18 g, 30 mmol), 3,4-(methylenedioxy)-phenylbo-
ronic acid (1.8 g, 11 mmol) and Pd EnCat™40 (937 
mg, 5%). The resulting mixture was stirred at 45°C 
for 2 h and then filtered. The catalyst was washed with 
H
2
O and CH
2
Cl
2
. The aqueous phase was extracted 
with CH
2
Cl
2
. The combined organic layers were dried 
over Na
2
SO
4
 and concentrated under reduced pressure. 
The crude residue was purified by flash chromatogra-
phy using hexane–EtOAc as eluent to give 4 (1.4 g) as 
a gray powder.
Gray solid (yield 57%); mp: 155–156°C; 1H NMR 
(400 MHz, CDCl
3
, δ): 7.75 (s, 1H, H-2), 7.1 (d, J 
= 2.0 Hz, 1H, H-2′), 6.94 (dd, J = 8.0 and 2.0 Hz, 
1H, H-6′), 6.83 (d, J = 8.0 Hz, 1H, H-5′), 6.44 (d, J 
= 2.2 Hz, 1H, H-6), 6.37 (d, J = 2.2 Hz, 1H, H-8), 
5.97 (brs, 2H, O–CH
2
–O), 3.94 (s, 3H, OCH
3
), 
3.89 (s, 3H, OCH
3
); 13C NMR (100 MHz, CDCl
3
, 
δ): 175.09 (C=O), 164.02 (C7), 161.54 (C5), 160.30 
(C9), 150.05 (C2), 147.58 (C3′), 147.58 (C4′), 126.5 
(C3), 126.04 (C1′), 122.84 (C6′), 110.50 (C2′), 110.0 
(C10), 108.35 (C5′), 101.30 (O–CH
2
–O), 96.74 
(C6), 92.73 (C8), 56.41 (OCH
3
), 55.79 (OCH
3
); IR 
(KBr): ν = 1654, 1456, 1247 cm-1; HRMS (ESI) m/z: 
[M+H]+ calculated for C
18
H
14
O
6
+H+, 327.086300; 
found, 327.086206.
3-(3′,4′-dihydroxyphenyl)-5,7-dimethoxy-4H-
chromen-4-one 5
A mixture of 4 (1.4 g, 4.3 mmol) and Pb(OAc)
4
 (7.5 
g, 17 mmol, freshly recrystallized from AcOH) in dry 
C
6
H
6
 (100 ml) was stirred at 80°C under argon over-
night. After, being cooled to room temperature, the 
reaction mixture was filtered through a pad of Celite, 
washed with CH
2
Cl
2
 and concentrated under reduced 
pressure. The crude was diluted with THF/H
2
O = 
5:1 (50 ml) and CH
3
COOH (50 ml), and the result-
ing mixture was stirred at room temperature for 6 h. 
Afterward, a saturated aqueous NaHCO
3
 solution was 
added until pH 8 and extracted with EtOAc. To the 
combined organic layers was added a solution of NaOH 
0.1 M. Water layer was treated with CH
3
COOH and 
then extracted with EtOAc. The combined organic 
layers were dried over Na
2
SO
4
 and concentrated under 
reduced pressure to obtain 5 (570 mg).
Yellow solid (yield 42%); mp: 127–129°C; 1H NMR 
(400 MHz, CH
3
OD): 7.86 (s, 1H, H-2), 6.88 (brs, 
1H, H-2′), 6.70 (brs, 2H, H-5′ and H-6′), 6.50 (d, J 
= 2.0 Hz, 1H, H-6), 6.40 (d, J = 2.0 Hz, 1H, H-8), 
3.80 (s, 3H, OCH
3
), 3.79 (s, 3H, OCH
3
); 13C NMR 
(100 MHz, CH
3
OD, δ): 175.00 (C=O), 165.08 (C7), 
161.13 (C5), 159.91 (C9), 151.28 (C2), 145.12 (C3′), 
145.0 (C4′), 126.49 (C3), 123.12 (C1′), 120.50 (C6′), 
116.99 (C2′), 110.00 (C10), 114.48 (C5′), 95.86 (C6), 
92.82 (C8), 55.09 (2 × OCH
3
); IR (KBr): ν = 3376, 
1637 cm-1; HRMS (ESI) m/z: [M+H]+ calculated for 
C
17
H
14
O
6
+H+, 315.086300; found, 315.086363.
3-(3′,4′-bis(3-methylbut-2-enyloxy)phenyl)-5,7-di-
methoxy-4H-chromen-4-one; GlaB. To a solution of 5 
(570 mg, 61.8 mmol) in acetone (100 ml) was added 
K
2
CO
3
 (7.4 g, 5.4 mmol) and, after 10 min of stir-
ring at room temperature, was added 3,3-dimethylallyl 
bromide (968 mg, 6.5 mmol). Then, the mixture was 
stirred at 80°C overnight. Afterward, the solvent was 
evaporated. The resulting solid was dissolved in EtOAc 
and extracted with water. The combined organic lay-
ers were dried over Na
2
SO
4
 and finally concentrated 
under reduced pressure. The crude was purified by 
column chromatography using hexane–EtOAc as elu-
ent to obtain GlaB as white powder. The powder was 
 recrystallized from hexane resulting with white crystals.
White crystal (yield 90%); mp 102–104°C. The 
spectral data of this product were identical to an 
authentic sample of GlaB.
Formulation of the NCs
Encapsulation protocol
NC-GlaB were prepared by using three poly(lactic-co-
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glycolic acid) (PLGA) polymer derivatives: the 
commercially available PLGA, PEGylated PLGA 
(PLGA–PEG) conjugates capable of prolonged blood 
circulation profile and PLGA–PEG conjugated with 
diethylene triamine pentaacetic acid (DTPA; PLGA–
PEG–DTPA), which allows the tracking of NCs in 
vivo by γ scintigraphy. NCs containing GlaB were pre-
pared using the nanoprecipitation method described 
by Fessi et al. (Figure 1) [29]. Briefly, 2.5 ml of acetone/
ethanol (60:40 v/v) containing polymer (the com-
mercially available PLGA [100%], PLGA–NH–PEG 
[100%] or PLGA–NH–PEG/PLGA–NH–PEG–
DTPA [90%:10%]) (12.5 mg), castor oil (75 μl), 
GlaB (4 mg) and soybean lecithin (12.5 mg) was added 
dropwise into 5 ml of aqueous phase (containing 0.2% 
of hydrophilic surfactant Tween® 80). The mixture 
was stirred in the hood for 30 min to allow solvent dif-
fusion and NC formation. Subsequently, the organic 
solvents were removed via rotatory evaporation under 
reduced pressure in a Buchi Rotavapor® (Buchi, UK). 
Finally, the volume of suspension was adjusted to 5 ml.
Solubility of GlaB in castor oil
The solubility of GlaB in castor oil was evaluated using 
the simple saturation shake-flask method [30]. Briefly, 
excess GlaB (10 mg) was transferred to vials contain-
ing 1 ml of castor oil, sealed and incubated at 37°C for 
48 h with shaking (250 strokes/min). Subsequently, 
100 μl of the supernatant was diluted in ethanol, and 
the amount of GlaB dissolved in the organic solvent 
was determined using a UV–Vis spectrophotometer 
(UV-1601 PC, Shimadzu, Japan) by measuring the 
absorbance at 258 nm, against a GlaB standard curve.
Determination of GlaB encapsulation efficiency
To purify the sample from un-encapsulated drug, NCs 
were passed through a PD10 desalting column (GE 
Healthcare). To disrupt the NCs and quantify the total 
amount of drug in NCs prior and after purification, 
NC preparations (30 μl) were diluted in ethanol (to 
a final volume of 2 ml). Subsequently, the amount of 
GlaB in NCs was determined using a UV–Vis spec-
trophotometer (UV-1601 PC, Shimadzu) by measur-
ing the absorbance at 258 nm against a standard plot 
of known GlaB concentrations. The amount of GlaB 
in the measured samples was then calculated from 
the standard plots (Supplementary materials) and the 
encapsulation efficiency (EE, %) was calculated using 
the following equation:
EE (%) = ([Drug] encapsulated/[Drug] total) × 100
Drug loading efficiency (% LE) was calculated using 
the following equation:
% LE = amount of GlaB encapsulated (mg)/(weight of 
polymer) × 100
Physico-chemical characterization of NCs
Size & ζ potential
The average size and ζ potential of the NCs were mea-
sured by dynamic light scattering with a Nanosizer 
ZS Series (Malvern Instruments, MA, USA), using 
disposable polystyrene cells and plain-folded capillary 
Zeta cells. Dilutions were prepared in deionized water 
and measurements performed at room temperature. 
The electrophoretic mobility was used to calculate the 
ζ potential using the Helmholtz–Smoluchowski equa-
tion. Results for the hydrodynamic size are presented 
as the average of 20 measurements, each performed in 
triplicate.
Release profile & serum stability in vitro
About 2 ml of NC formulation containing 2 mg (GlaB) 
in 5 ml was transferred into a 10 kDa dialysis bag, and 
dialysis was performed against 200 ml of phosphate-
buffered saline (PBS; pH 7.4) containing 10% (w/v) 
Tween® 80, at 37°C under stirring (250 strokes/min). 
Samples were taken after 24 h, and drug concentration 
was determined using a Perkin-Elmer Lambda 35 UV–
Vis spectrophotometer by measuring the absorbance at 
258 nm.
Shelf life stability
NC suspensions were transferred to 7 ml glass vials, 
sealed and stored at 4°C. The stability of NCs was 
tested after 0, 7, 14 and 28 days by visual inspection 
(color and opacity) and by measuring the hydrody-
namic size and ζ potential. Results of measurements 
(n = 3) are presented as average ± standard deviation 
(SD).
Cell culture
SKOV3 human ovary adenocarcinoma cell line was 
cultured in McCoy media, while PANC1 human 
pancreatic carcinoma cell line and GL261 murine 
glioma cell line were cultured in Advanced Roswell 
Park Memorial Institute (RPMI) media (Sigma, MO, 
USA), at 37°C in 5% CO
2
. Culture medium was sup-
plemented with 10% fetal bovine serum (FBS), 100 U/
ml penicillin, 100 μg/ml streptomycin and 1%  l -glu-
tamine (Sigma). Cells were routinely grown in 75 cm2 
tissue culture flasks and passaged twice a week, after 
detachment with trypsin/EDTA (Sigma), when reach-
ing 80% confluency.
Human (G7) and mouse glioma-initiating neural 
stem cell line (IENS) glioblastoma (GBM), as well 
as their culturing conditions, have been described 
previously [31–34]. Briefly, cells were cultured using 
www.futuremedicine.com 715
Figure 1. Synthesis of Glabrescione B. Reagents and conditions: (i) boron tribromide, dry dichloromethane, RT, 2 h; (ii) DMF–DMA, 
95°C, 3 h; (iii) iodine, methanol, RT, 1 h; (iv) 3,4-(methylenedioxy)-phenylboronic acid, PdEnCat™ 40, sodium carbonate, DME/H2O 
1:1 (v/v), 45°C, 2 h; (v) lead tetracetate, benzene dry, 80°C, overnight; (vi) acetic acid, THF/H2O (5:1 v/v), RT, 1 h; (vii) 3,3-dimethylallyl 
bromide, potassium carbonate, acetone, reflux, 72 h. 
RT: Room temperature.
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serum-free complete media (described in Supplemen-
tary materials) supplemented with B27 (Life Tech-
nologies, UK, 17504044) and N2 (Life Technologies, 
17502048). Growth factors EGF (Peprotech, UK, 
315–09–500) and FGF-2 (Peprotech, 100–18B-500) 
(10 ng/ml), as well as laminin (Sigma, L2020, 1 μg/
ml), were added freshly before cell split. Cells were rou-
tinely grown to confluence and split typically twice per 
week after dissociation with Accutase solution (Sigma, 
A6964) and centrifugation. Differentiation of G7 cells 
was performed as described previously by Pollard and 
collaborators [35]. After reaching 70% confluency, G7 
cells were washed with PBS and replaced with media 
containing bone morphogenetic protein (BMP)4 
(Peprotech 120–05ET-10, 10 ng/ml), but no EGF or 
FGF-2. Differentiation media, containing BMP, was 
replaced every 7 days throughout the time course and 
supplemented with fresh BMP at 4 days.
Cytotoxicity studies in vitro
Cells seeded in 96-well plates were incubated with 
GlaB or NC-GlaB (200 μl final volume in complete 
media) for 48, 72 and 96 h. Subsequently, the media 
was removed and replaced with 120 μl of MTT solu-
tion (0.5 mg/ml). Cells were incubated for 3 h in 
normal culture conditions, after which the formazan 
crystals were dissolved in DMSO (200 μl) and sam-
ple absorbance at 570 nm was measured in a FLUO 
star OPTIMA plate reader (BMG Labtech, UK). The 
results, expressed as the percentage cell survival (mean 
± SD), were calculated using the following equation: 
% cell survival = (A570 nm of treated cells/A570 nm 
of untreated control cells) × 100.
Cell cycle analysis by flow cytometry
The percentage of cells in each phase of the cell cycle 
was determined by flow cytometry. Briefly, cells seeded 
in 24-well plates (5 × 104) were treated with 5 μM of 
GlaB, NC-GlaB or equivalent concentrations of empty 
NCs. After treatment, cells were washed with PBS, 
trypsinized and transferred into BD flow cytometer 
tubes. After centrifugation at 500 × g for 5 min (for 
trypsin removal), cells were fixed by incubation with 
70% cold ethanol for 1 h. After washing with PBS (to 
remove traces of ethanol), fixed cells were treated with 
50 μl of RNase A in PBS (100 μg/ml, 10 min at 37°C), 
to ensure that RNA labeling does not interfere with the 
results. Subsequently, cells were stained for 30 min at 
37°C in the dark with 400 μl of propidium iodide (PI) 
solution (40 μg/ml of PI in PBS). PI fluorescence was 
then measured in the FL-2 channel using a BD FACS 
Calibur flow cytometer (BD Bioscience, CA, USA). 
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For each condition, 10,000 events were gated and 
fluorescence was analyzed using the FlowJo software. 
Results were expressed as averages of percentage cell 
populations in each phase of the cell cycle ± SD (n = 3).
Western blot analysis
SKOV3, PANC1, GL261, G7 and IENS GMB cells 
were cultured on 6-well plates and incubated with cul-
ture media for 24 h. PANC1 and SKOV3 cells were 
cultured on 6-well plates and incubated with 5 μM 
GlaB for 24 or 48 h. At the end of the treatment, 
cells were rinsed twice with ice-cold PBS, incubated 
with RIPA buffer (radioimmunoprecipitation Assay 
buffer, 1% triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris-HCl and 0.15 M NaCl, pH 8) 
containing protease inhibitor (Complete Ultra, Roche 
Diagnostics GmbH, Germany). Cells were scrapped 
out and the collected lysates were kept on ice for 
additional 30 min with intermittent vortexing every 
10 min. Lysate solutions were centrifuged at 17,949 × g 
for 30 min, and the supernatants containing cell pro-
teins were collected. The concentration of the isolated 
proteins was determined using BCA Protein Assay 
kits (Pierce BCA protein assay kit, Thermal Scientific, 
UK). About 100–200 μg of the protein was resolved in 
8% SDS-PAGE and electrophoretically transferred to 
Hybond ECL nitrocellulose membranes (GE Health-
care, UK). Membranes were blocked in 3% bovine 
serum albumin (Sigma-Aldrich, UK) at room tem-
perature for 1 h. Membranes were then incubated with 
the primary antibodies against Gli1 (rabbit antimouse 
antibody, PA5–23411; rabbit antihuman antibody, 
PA5–28384; Thermofisher Scientific, UK) at 1:1000 
dilution or GAPDH (#14C10, Cell Signaling Tech-
nology, CA, USA) at 1:5000 dilution over night at 
4°C. Membranes were washed three-times with Tris-
buffered saline containing 0.1% Tween® 20 (TBS-T) 
and then incubated with secondary antibodies, horse-
radish peroxidase-linked goat antirabbit antibodies 
(#7074, Cell Signaling Technology) at 1:3000 dilution 
for 2 h at room temperature. The protein bands were 
detected using chemiluminescent kits (Immun-Star™ 
 Chemiluminescent Kit, BioRad, UK) and imaged by 
the ChemiDoc MP imaging system and Image Lab 
software (BioRad). GAPDH was used as an internal 
protein control. Values for Gli1 were normalized to the 
total GAPDH and then to untreated IENS, in the case 
of treatment to untreated PANC1 and SKOV3.
Radiolabeling of NCs
Radiolabeling of NC–PEG–DTPA–GlaB
The radioactive probe 111InCl
3
 was purchased from 
Mallinckrodt Pharmaceuticals (The Netherlands) 
as an aqueous solution in 0.5 M HCl and used with-
out further purification. To radiolabel the NC with 
indium-111, NCs were prepared in water as described 
in the previous section except that PLGA–PEG–
DTPA was included at 10% (w/w) of total polymer 
content and concentrated 28-times using rotavap, so 
that the final drug and polymer concentrations are 
1.22 and 71.43 mg/ml, respectively. The NC suspen-
sion (700 μl) was incubated with 2 M ammonium 
acetate (one-ninth of the reaction volume, pH 5.5), to 
which 10 MBq of 111InCl
3
 was added per injection dose 
for γ scintigraphy. The reaction was kept at room tem-
perature for 30 min with intermittent vortexing every 
10 min. Upon completion, the radiolabeling reaction 
was quenched by the addition of 0.1 M EDTA che-
lating solution (one-twentieth of the reaction volume). 
111InCl
3
 alone and NCs without DTPA incorpora-
tion were also subjected to the same conditions of the 
 labeling reaction as a control.
Radiolabeling efficiency & serum stability studies
To evaluate the radiolabeling efficiency, the labeled 
NC-111In was spotted on the TLC strips, which were 
developed in 0.1 M ammonium acetate containing 25 
mM EDTA as a mobile phase. Strips were allowed to 
dry before being developed and counted quantitatively 
using a cyclone phosphor detector (Packard Biosci-
ences, UK). The NC-111In was passed through PD-10 
column before injecting into animals to exchange the 
ammonium acetate buffer (pH 5.5) with PBS (pH 7.4) 
and to ensure that no free 111In-EDTA was present in 
the injected dose. The sample was collected from the 
column and the radiolabeling efficiency was exam-
ined immediately after the collection. As a result, the 
sample was further diluted two-times to three-times 
compared with the original sample. Final drug concen-
tration after filtration was 1.22 mg/ml. To determine 
the stability of the radiolabeled NC-111In, 20 μl of the 
sample was incubated with 20 μl of serum and 20 μl 
of PBS at 37°C. At 24 h, 2 μl of the incubated samples 
was spotted to the TLC strips, which were developed 
and quantified as described above. Free 111In-EDTA 
was detected at the solvent front while radiolabeled NC 
was retained at the application point. Indium-labeled 
NC without DTPA incorporation was included as a 
control.
Tumor xenograft animal model studies
All animal experiments were performed in compli-
ance with the UK Home Office Code of Practice for 
the Housing and Care of Animals Used in Scientific 
Procedures. Six- to eight-week-old female SCID/Beige 
mice (Harlan Laboratories, UK) were caged in indi-
vidually vented cages in groups of four with free access 
to food and water. A temperature of 19–22°C was 
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maintained, with a relative humidity of 45–65%, and 
a 12 h light/dark cycle. Established human pancreatic 
PANC1 and PANC0403 xenograft tumor models were 
applied. Mice were inoculated subcutaneously with 
1 × 106 cells in 100 μl on either flanks subcutaneously.
Tissue biodistribution by γ scintigraphy
Forty days after tumor inoculation, pancreatic-tumor-
bearing SCID/Beige mice (n = 2 per time point) were 
injected intravenously, via tail vein, with 200 μl of 
NCs at a dose of 115 mg/kg of polymer and 18.5 mg/
kg of drug containing approximately 1 MBq of radio-
activity (∼2.3 mg of polymer, ∼370 μg of drug, 1 MBq 
per mouse). Animals were sacrificed after 30 min or 
24 h. The tumors and major organs (brain, lung, liver, 
spleen, kidney and heart) were collected, weighed, and 
the 111In activity in the collected tissues was quanti-
fied using an automated γ counter (LKB Wallac 1282 
Compugamma, Perkin Elmer, UK). A portion of the 
radiolabeled NCs was also analyzed as a reference. The 
γ counter corrected for physical radioisotope decay. 
Radioactivity readings (c.p.m.) were plotted as a % 
ID/organ or as a % ID/g of tissue.
Organ toxicity evaluation
Twenty-eight days after tumor inoculation, pancreatic-
tumor-bearing SCID/Beige mice (n = 6) were injected, 
via tail vein, with 200 μl of the NCs at a dose of 78 
mg/kg of polymer and 12.5 mg/kg of drug (∼1.56 mg 
of polymer and ∼250 μg of drug per mouse) once a 
week for 3 weeks. At the experiment end point, the 
mice were sacrificed and the major organs (liver, lung, 
tumor, heart, kidney and spleen) were fixed in 10% 
neutral buffer formalin as 5 mm2 pieces. The organs 
were then paraffin-embedded and sectioned for hema-
toxylin and eosin according to the standard histo-
logical protocols at the Royal Veterinary College. The 
stained sections were analyzed with a Leica DM 1000 
LED Microscope (Leica Microsystems, UK) coupled 
with charge-coupled device (CDD) digital camera 
(Qimaging, UK).
Results
Synthesis of GlaB
The synthesis of the GlaB (Figure 1) began from com-
mercially available 2′,4′,6′-trimethoxyacetophenone. 
The O-demethylation was selectively obtained in posi-
tion 2 by treatment of 2′,4′,6′-trimethoxyacetophenone 
with boron tribromide (BBr
3
) to give 2′-hydroxy-
4′,6′-dimethoxyacetophenone 1. Compound 1 was 
subsequently treated with N,N-dimethylformamide 
dimethyl acetal to form the enamino ketone 2, which, 
on stirring in methanol with excess iodine, underwent 
tandem cyclization and iodination to afford 3-iodo-
5,7-dimethoxy-4H-chromen-4-one 3 [36]. Cross-cou-
pling of 3 with 3,4-(methylenedioxy)-phenylboronic 
acid in the presence of Pd EnCat™40 catalyzed 
Suzuki reaction gave 3-(3′,4′-methylendioxyphenyl)-
5,7-dimethoxy-4H-chromen-4-one 4. Notably, the 
Suzuki–Miyaura reaction was accomplished by the use 
of polyurea-encapsulated palladium (Pd EnCat™ 40), 
a robust and recyclable catalyst which was designed 
in 2002 [37] and used under mild conditions [38]. The 
methylene acetal in 4 was oxidatively removed by treat-
ment with Pb(OAc)
4
 allowing the clean formation of 
acetoxy acetal, which was smoothly hydrolyzed to pro-
vide the desired catechol 5 [39]. The final step was the 
prenylation of compound 5, which was accomplished 
by treatment with 3,3-dimethylallyl bromide and 
K
2
CO
3
 under refluxing acetone to yield GlaB [40]. The 
spectral data of GlaB obtained by synthesis were iden-
tical to those found in the natural product. The overall 
reaction yield was 7%.
Formulation & physico-chemical 
characterization of NCs
The preparation of non-PEG-containing NC (NC-
GlaB) is described in detail in the ‘Materials & meth-
ods’ section. PEG-containing NCs (NC-PEG) were 
also prepared, due to their prolonged blood circulation 
time facilitated by PEG. All formulations were pre-
pared using the nanoprecipitation method (Figure 2). 
The purified formulations were then characterized for 
their hydrodynamic diameter, PDI and ζ potential, 
immediately after purification and over 28 days stor-
age at 4°C (Table 1 & Supplementary Table 1). Castor 
oil was selected as the core material due to its good oil 
solubilization ability of the drug (27 μg/μl at 37°C). 
Importantly, efficient drug encapsulation (∼90%) 
was achieved for both NC-GlaB and NC-PEG-GlaB 
(Table 1 & Supplementary Table 1). In contrast to the 
extremely poor aqueous solubility of GlaB [21], NC-
GlaB were well dispersed and formed a homogeneous 
suspension in aqueous media with PDI values below 
0.2 and an average hydrodynamic diameter of approxi-
mately 160 nm. All NC formulations were found to be 
stable over the 28-day storage period, with no signifi-
cant changes in size, PDI or ζ potential observed over 
time. No apparent change in color or phase separation 
was observed in any of the formulations.
In vitro stability of the NCs
To determine the in vitro stability of GlaB in the NC 
formulation, drug release from NC–PEG–GlaB was 
assessed over 24 h by the dialysis method, in the pres-
ence or absence of FBS. The dialysate used was PBS 
pH 7.4 containing 10% w/v Tween® 80 to main-
tain GlaB solubility in aqueous media. As shown in 
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Figure 2. Schematic representation of the formulation method of the oil-cored nanocapsules. The organic phase, 
composed of polymer, oil, lipophilic surfactant and the drug dissolved in a water-miscible solvent, was added 
dropwise to an aqueous phase containing a hydrophilic surfactant. Formation of NCs takes place by solvent 
diffusion and polymer precipitation. Finally, the solvent was removed forming an aqueous dispersion of the NC. 
The average diameter of the NCs is approximately 160 nm. 
NC: Nanocapsule.
Organic 
phase
Organic solvent evaporation
<200 nm
PLGA shell
Castor oil
GlaB
Water phase
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Figure 3, drug release from the NC formulation did not 
exceed 20% over the course of 24 h, a value that was 
not altered by the presence of 50% FBS.
In vitro cytotoxicity of GlaB
The MTT assay was performed in order to estimate 
the toxicity of free or NC-formulated GlaB. Two dif-
ferent types of cell lines were selected for this study: 
non-stem cancer cells that contain a small CSC sub-
population (PANC1, human pancreatic carcinoma; 
SKOV3, human ovary adenocarcinoma; and GL261, 
murine glioma) [41–43] and pure glioblastoma-derived 
neural stem cells (GNS; patient-derived G7 human 
and engineered Ink4a/ARF, EGFRvIII overexpressed 
Table 1. Shelf-life stability of oil-cored nanocapsules prepared using PLGA as polymer.
Sample Day Hydrodynamic 
diameter†,‡
PDI†,‡ ζ potential 
(mV)‡,§
Encapsulation 
efficiency (% EE)‡,¶
Loading efficiency 
(% LE)‡,# 
NC 1 164.0 ± 1.9 0.19 ± 0.01 -54.0 ± 1.8 – –
 7 162.4 ± 1.2 0.18 ± 0.01 -59.3 ± 0.2   
 14 151.1 ± 0.8 0.14 ± 0.01 -67.8 ± 1.6   
 21 155.6 ± 1.5 0.17 ± 0.02 -56.2 ± 0.6   
 28 166.1 ± 1.3 0.21 ± 0.01 -57.6 ± 0.7   
NC-GlaB 1 159.4 ± 1.0 0.17 ± 0.01 -39.8 ± 0.5 85 ± 6.1 27.5 ± 1.9
 7 155.9 ± 0.4 0.12 ± 0.02 -47.0 ± 0.6   
 14 148.6 ± 1.0 0.13 ± 0.02 -58.0 ± 1.8   
 21 154.8 ± 0.9 0.14 ± 0.02 -49.7 ± 1.5   
 28 154.3 ± 1.1 0.14 ± 0.01 -46.7 ± 1.7   
†Measured with dynamic light scattering.
‡Expressed as mean ± SD (n = 3).
§Analyzed with electrophoretic light scattering using 10 mM NaCl.
¶Calculated as percentage of initial drug added, which was determined by spectrophotometry.
#Calculated as mass of incorporated drug divided by the weight of polymer, which was determined by spectrophotometry.
GlaB: Glabrescione B; NC: Nanocapsule; NC-GlaB: GlaB-loaded oil-cored polymeric nanocapsule; PDI: Polydispersity index; SD: Standard 
deviation.
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Figure 3. Release profile of glabrescione B from 
nanocapsules. NC–PEG–GlaB were dialyzed for 24 h 
against 10% w/v Tween® 80 in PBS, pH 7.4, in the 
presence or absence of 50% FBS. Drug concentration 
inside the dialysis bag was assessed by measuring the 
absorbance at 258 nm. Results are expressed as means 
± standard deviation (n = 3). 
FBS: Fetal bovine serum; NC-PEG-GlaB: PEG-containing 
nanocapsules loaded with GlaB; GlaB: Glabrescione B; 
PBS: Phosphate-buffered saline.
20
40
60
0
100
80
PBS 50% FBS
%
 G
la
B
 r
el
ea
se
d
future science group
Polymeric glabrescione B nanocapsules for tumor therapy in vitro    Research Article
IENS murine) [31]. It is hypothesized that the GNS 
cell lines will be more sensitive to GlaB as they consist 
entirely of CSCs and therefore have a stronger depen-
dence on the Hh pathway. Indeed, western blot quan-
tification of Gli1 protein expression, a downstream 
effector in the Hh pathway, showed higher Gli1 pro-
tein levels in pure CSCs (IENS and G7), compared 
with non-stem cancer cells (PANC1, SKOV3 and 
GL261) (Supplementary Figure 1).
As demonstrated in Figure 4A & Supplementary 
 Figure 2, a dose-dependent and time-dependent 
reduction in cell viability was observed in both treat-
ment conditions (NC-GlaB and free GlaB). Incu-
bation for 96 h with 5 μM of free GlaB/NC-GlaB 
resulted in a significant reduction in cell viability in 
IENS (∼27%/14% cell viability; p < 0.05) and G7 
(∼20%/13%; p < 0.001/p < 0.01) cells, while a smaller 
decrease was seen in GL261 (∼67%/84%; p > 0.05) or 
PANC1 (∼36%/48%; p > 0.05) cells. Light micros-
copy images obtained during treatment confirmed 
the dose-dependent cell killing effect verified with the 
MTT assay. Morphological changes, namely smaller 
and more round, were observed during incubation with 
free GlaB or NC-GlaB (Figure 4C). Cells treated with 
empty NCs, at equivalent concentrations to those used 
in NC-GlaB, showed normal cell morphology except 
at very high concentration, in which slight but signifi-
cant toxicity was detected (Supplementary Figure 3).
IC
50
, the drug amount required to achieve 50% cell 
kill, was estimated in G7 and PANC1 cells. The val-
ues obtained following 96 h treatment with free GlaB/ 
NC-GlaB were 0.29 μM/0.71 μM (G7) and 1.62 
μM/1.49 μM (PANC1) (Figure 4B). The toxicity of 
NC–PEG–GlaB was also tested, to assess whether the 
incorporation of PEG into the NCs has any effect on 
cell viability. Comparable results were obtained at 96 
h with 5 μM GlaB, for NC–PEG–GlaB (∼74%) and 
NC–GlaB (∼86%) (Supplementary Figure 4).
GlaB effect on cell cycle
Having shown that free or NC-formulated GlaB 
has an effect on the viability of GNS cells and, to 
a lesser extent, on non-stem cancer cells, experi-
ments were performed to determine whether the 
effect could be due to alterations in the cell cycle 
mechanism. As shown in Figure 5 (left panel) and 
Supplementary Figure 5, a steady increase in cell cycle 
arrest at G2 phase was detected after IENS treatment 
with 5 μM of NC-GlaB at 24 and 48 h (∼25.3 and 
30.2% of cells in G2, respectively), when compared 
with untreated cells (∼15.0 and 5.3%). Similar values 
were obtained for treatment with 5 μM of free GlaB 
(∼26.7 and 24.8%). In the case of the PANC1 cells 
(Figure 5, right panel & Supplementary Figure 4), a 
shift in cell cycle distribution from G1 to S phase was 
observed with GlaB treatments at 24 and 48 h (∼35.5 
and 37.9% of cells in the S phase, respectively), com-
pared with untreated cells (∼25.2 and 24.6%). A sig-
nificant shift in the cell cycle profile was not detected 
in PANC1 cells incubated with NC-GlaB.
Effect of GlaB treatment on Gli1 protein 
expression, analyzed by western blot
Since not enough protein could be obtained from IENS 
or G7 cells treated with GlaB, due to high sensitivity 
to the drug, PANC1 and SKOV3 were selected to fur-
ther clarify the influence of GlaB incubation on Gli1 
protein levels. In this regard, decreased Gli1 expression 
was detected in the cells after incubation with 5 μM 
GlaB for 24 h (∼73.3% relative expression for SKOV3, 
88.1% for PANC1) or 48 h (∼33.6% for SKOV3, 
44.6% for PANC1), compared with control untreated 
cells (100%) (Supplementary Figure 6). These results 
suggest that GlaB treatment suppresses the expression 
of Gli1.
Effect of GlaB treatment in differentiated CSCs
In order to confirm that the activity of GlaB is Hh 
dependent (and thus connected to stemness), the dif-
ferentiation of G7 cells into astrocytes was promoted 
by incubating these cells with BMP4, as shown pre-
viously by Carén et al. [35]. It is expected that differ-
entiated G7 cells are less dependent on Hh pathway 
and therefore less sensitive to GlaB. Indeed, as shown 
in Figure 6A & B, and opposed to what was observed 
with pristine G7 cells, no significant toxicity was seen 
in differentiated G7 cells incubated with free GlaB for 
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Figure 4. In vitro cytotoxicity of glabrescione B and glabrescione B-loaded oil-cored polymeric nanocapsules. Cells were incubated 
with GlaB or NC-GlaB for 96 h at increasing drug concentrations (1–100 μM). (A) Cell viability, expressed as a percentage of control 
untreated cells, was determined by MTT assay after 96 h incubation with free GlaB (left) or NC-GlaB (right) treatments. (B) GlaB and 
NC-GlaB dose–response curve and IC50 values for GNS-G7 (left) and PANC1 cells (right) after 96 h treatment with GlaB or NC-GlaB at 
increasing drug concentrations (from 0.05–1 to 100 μM). Results are expressed as mean ±SD (n = 5). (C) Microscopic observation of 
cells at 96 h after treatment with GlaB, NC-GlaB or empty NC, at a final concentration of 5 μM GlaB. Scale bar corresponds to 150 μm. 
GlaB: Glabrescione B; NC: Nanocapsule; NC-GlaB: GlaB-loaded oil-cored polymeric nanocapsule; SD: Standard deviation.
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Figure 5. Cell cycle analysis in cultured IENS and PANC1 cells after treatment with glabrescione B. (A) Representative histograms 
showing the cell cycle distribution and (B) relative changes in the percentage of cells in each cell cycle phase, following incubation for 
48 h with 5 μM GlaB. Results are expressed as mean ± standard deviation (n = 3). 
GlaB: Glabrescione B; NC: Nanocapsule; NC-GlaB: GlaB-loaded oil-cored polymeric nanocapsule.
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the tested concentrations except the highest (50 μM). 
This unexpected toxicity could be due to crystal forma-
tion at such high drug concentration. When incubated 
with NC-GlaB at all the tested concentrations, no sig-
nificant cytotoxicity was observed in differentiated G7 
cells (Figure 6A & C; Supplementary Figure 7).
Radiolabeling of NC-PEG-GlaB & in vitro 
stability
In order to perform in vivo biodistribution studies, 
radiolabeled NCs were prepared using the previously 
synthesized PLGA–NH–PEG–NH–DTPA at 10% 
(w/w) of total polymer content. The presence of DTPA 
in the shell of the NCs is necessary for complexing 
111In, a useful short-lived γ emitter used in biodistribu-
tion studies. The radiolabeling efficiency, calculated as 
the percentage of bound 111In of total added 111In, was 
tested using instant thin layer chromatography (TLC) 
technique after chelation of 111In. Only [111In]–EDTA 
or [111In]–DTPA chelates migrated to the solvent front 
while the radiolabeled polymer remained at the appli-
cation point. Approximately 90% of radiolabeling 
efficiency was achieved for NC–DTPA (Figure 7A). 
Buffer exchange from ammonium acetate to PBS was 
also carried out using gel filtration chromatography. By 
passing the NC suspension through PD10 size exclu-
sion columns, unbound 111In was retained in the col-
umn and the eluted NC suspension (in PBS) was ready 
for injection to mice. Radiolabeled NCs were found to 
be stable in solution, with approximately 92 and 72% 
stability obtained after NC incubation in PBS or 50% 
FBS (respectively) at 37°C for 24 h.
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Figure 6. In vitro cytotoxicity of glabrescione B and glabrescione-B-loaded oil-cored polymeric nanocapsules in normal or 
differentiated G7 cells. Cells were incubated with GlaB or NC-GlaB for 96 h at increasing drug concentrations (1–100 μM). 
(A) Microscopic observation of cells after treatment with GlaB or NC-GlaB for 96 h at 5 and 50 μM of GlaB (scale bar corresponds to 
150 μm). Cell viability after 96 h of treatment with (B) free GlaB or (C) NC-GlaB was determined by MTT assay. Results, expressed as 
percentage to control untreated cells, correspond to mean ±SD of five different experiments. 
GlaB: Glabrescione B; NC: Nanocapsule; NC-GlaB: GlaB-loaded oil-cored polymeric nanocapsule; SD: Standard deviation.
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Biodistribution of radiolabeled NC–PEG–GlaB 
in mice after single intravenous injection
The biodistribution of radiolabeled NC–PEG–
DTPA–GlaB was investigated in pancreatic-tumor-
bearing SCID/Beige mice. After receiving a single tail 
vein injection of NCs (∼370 μg GlaB per mouse), the 
animals were sacrificed at 30 min or 24 h postinjection 
and the % ID/g of tissue and % ID/organ were calcu-
lated. As shown in Figure 7B & C, NCs showed accu-
mulation in major first-pass organs such as liver and 
spleen at 24 h after injection. Tumor uptake was 1.2 
and 0.3% ID/g at 30 min and 24 h, respectively. Mice 
were not perfused before sacrifice. It is therefore likely 
that the higher % ID/g tumor obtained at 30 min than 
24 h is due to high concentration of the drug in the 
blood.
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Figure 7. Radiolabeling of NC-PEG with 111In, stability and in vivo biodistribution. (A) TLC of the radiolabeled NCs immediately after 
radiolabeling and after desalting using PD10 desalting column, after concentrating the sample and just prior injection. No free 111In 
was detected in all the samples. A single dose of radiolabeled NCs was administered to SCID/Beige mice, via tail vein. (B) Percentage 
injected dose per gram of organ (% ID/g of organ) and (C) percentage injected dose per organ (% ID/organ), at 0.5 and 24 h after 
injection of 370 μg GlaB/mouse. Insets show the uptake in tumors. Data were expressed as means ± standard deviation (n = 2). 
GlaB: Glabrescione B; ID: Injected dose; NC: Nanocapsule.
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Histological examination of major organs 
following multiple injections of radiolabeled 
NC–PEG–GlaB in mice
To evaluate the systemic toxicity of radiolabeled 
NC–PEG–DTPA–GlaB, pancreatic tumor- bearing 
SCID/Beige mice were injected with the NCs 
(∼250 μg GlaB/mouse), via tail vein, once a week for 
3 consecutive weeks. Histological analysis, carried 
out on hematoxylin and eosin stained tissue sections, 
did not show significant changes in lung, heart, kid-
ney, liver and spleen compared with untreated (naive) 
tissues (Figure 8). This initially suggests that the 
NC–PEG–GlaB formulation can be administered 
via systemic injection. Extensive biocompatibility 
studies of this  nanoformulation need to be assessed 
in the future.
Discussion
CSCs are emerging as key therapeutic targets in oncol-
ogy, as their efficient elimination may offer long-last-
ing tumor remission or even potentially disease-free 
treatment outcomes for patients. In this regard, a sub-
stantial amount of evidence suggests that CSCs rely on 
ligand–receptor-mediated signaling pathways, namely 
Hh, Wnt and Notch, for strict control of cellular 
functions that impart cell fate, namely proliferation, 
self-renewal and differentiation [44,45]. Aberrant Hh 
signaling is found in the majority of the human can-
cers, including brain tumors [18], and is usually caused 
not only by mutations in Hh pathway components 
(e.g., receptors) but also by high expression of Hh 
ligands [13], Hh signaling, which plays an important 
role in stem cell renewal, is epigenetically regulated in 
724 Nanomedicine (Lond.) (2017) 12(7)
Figure 8. Organ histology for NSG (NOD/SCID gamma) 
mice treated with multiple nanocapsule injections. NSG 
mice were injected intravenously with 250 μg of NC-
formulated GlaB once a week for 3 weeks. After the 
mice were sacrificed, the organs were immediately 
fixed in 10% neutral buffer formalin as 5 mm2 pieces. 
These pieces were then paraffin-embedded, sectioned 
for hematoxylin and eosin stains and imaged with light 
microscopy. Scale corresponds to 50 μm. 
GlaB: Glabrescione B; NC: Nanocapsule.
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CSCs mainly Gli transcription factors [46]. Targeting 
Hh signaling components or epigenetic regulators in 
CSC-driven tumors could therefore be of therapeutic 
interest.
To date, an inhibitor of Hh pathway receptor (Smo) 
– GDC-0449 – has been approved by US FDA and is 
currently used in clinics, whereas only a few Gli inhibi-
tors have been identified [47,48]. Therefore, novel drugs 
targeting Gli family members or downstream effectors 
would be beneficial for a wide spectrum of patients 
whose tumors have high Gli protein levels and/or 
activity. Furthermore, downstream activation of Gli 
function has been reported [49], with the development 
of resistance to Smo antagonists being observed fre-
quently during therapy. Recent in silico and in vitro 
screens of a library of natural compounds identified 
a lead candidate for Gli inhibition – GlaB [22]. GlaB, 
bearing the 5,7-dimethoxyisoflavone nucleus, was iso-
lated and characterized from the seeds of D. glabrescens, 
a Brazilian plant, in 1977 by Delle Monache et al. [21]. 
Since developed extraction methods allow us to get 
very limited amounts of pure isoflavone, here we pro-
vided the first total synthesis of GlaB which  foresees a 
six-step route with an overall yield of 7%.
The in vitro and in vivo GlaB activities were also 
tested in our previous study, with results showing 
impaired Hh oncogenic activity via inhibition of Gli1/
DNA interaction [22]. This provided proof of con-
cept for the therapeutic relevance of an Hh-target-
ing approach focused on a downstream Gli effector 
rather than on upstream oncogenic deregulated sig-
nals. However, the native GlaB molecule is insoluble 
in water (solubility is 0.02 μg/ml), which will likely 
translate into poor bioavailability in vivo. In a previ-
ous study from our group, the efficacy of GlaB against 
MB-bearing and BCC-bearing mice was assessed [22]. 
A solution of GlaB, prepared in 2-hydroxypropyl-β-
cyclodextrin:ethanol (3:1), was injected subcutane-
ously, compromising drug bioavailability. In this study, 
the use of ethanol was replaced with the long-circu-
lating NC-GlaB, allowing intravenously injection of 
relatively high GlaB dose.
We have previously developed PEG-conjugated 
polymeric oil-cored NCs to enhance systemic delivery 
of therapeutic agents and active natural compounds as 
quercetin and curcumin [27,28]. Increased tumor uptake 
of folic-acid-conjugated NCs, containing quercetin, 
was observed after intravenous administration of in 
mice via passive and active targeting, while passively 
targeted curcumin-loaded PEG–PLGA NCs enhanced 
curcumin release into the tumor site after systemic 
administration, when compared with the free drug [28]. 
According to these studies, in an attempt to formulate 
NCs characterized by smallest size, narrowest PDI, 
higher colloidal stability and drug loading, different 
oil-cored types were used [28]. Among all, castor oil was 
found to be the one capable of obtaining the desired 
NCs [28]; thus, it has been selected as the most promis-
ing system to enhance GlaB bioavailability. In particu-
lar, GlaB was successfully loaded into NCs composed 
of castor-oil-cored offering approximately 70-fold 
increase in GlaB aqueous solubility (solubility in NC: 
∼700 μg GlaB/ml of NC). Regarding the choice of 
the polymer, different PLGA polymer derivatives were 
used depending on the experiment that needed to be 
performed. Both PEG–PLGA and DTPA–PEG–
PLGA were obtained through organic synthesis [28] 
and, in accordance with the previous studies [27,28], 
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the conjugation of PLGA with PEG leads to a slight 
increase (less negative) in surface charge of NC–PEG 
and NC–PEG–GlaB, probably due to neutralization 
of the negative carboxylate groups of PLGA (Table 1 & 
Supplementary Table 1). Importantly, empty NCs and 
NC-GlaB showed similar hydrodynamic size and sta-
bility over time, which suggests that the encapsulation 
of GlaB does not affect NC size and long-term storage. 
Comparable biological evaluation results were obtained 
for both NC and NC-PEG (Supplementary Figure 4) 
when tested in IENS at the three time points. The 
good in vitro serum stability data (<20% release over 
24 h) suggest that there will be minimal drug release 
from the NC in blood circulation and that most of the 
drug will be released at the target site, in other words, 
the tumor.
A series of in vitro functional assays were then per-
formed to evaluate and compare the anticancer prop-
erties of NC-GlaB and free GlaB. Cell lines for these 
studies were chosen, after literature consultation, on 
the basis of Hh status (dysregulated Hh pathway) 
and presence of stem-like cells in the cell population. 
In vitro results obtained from cell viability, cell cycle 
analysis and western blotting confirmed that CSC cell 
lines (G7, IENS) were more sensitive to GlaB than 
non-stem cancer cells (GL261, PANC1 and SKOV3), 
an effect that was mediated by Hh regulator Gli, which 
is more pronounced in CSCs. This was further con-
firmed by the fact that differentiated G7 cells were 
drug insensitive. Future studies will be performed to 
prove unequivocally that Hh signaling is dysregulated 
in the CSCs used in this study (G7, IENS).
The fact that GlaB was effective in killing CSCs at 
very low concentrations (∼70% cell killing with 1 μM 
for 48 h) is very encouraging and suggests a promis-
ing in vivo therapeutic outcome if such concentrations 
can be achieved in vivo following systemic injection. 
Moreover, these results are consistent with previous 
in vitro studies, in which GlaB (5 μM) was shown to 
inhibit proliferation of ex vivo cultured mouse granule 
cell progenitors, MB stem cells isolated from Ptch1± 
mice tumors and ASZ001 BCC cells, with a strength 
similar to GANT61 (10 μM) [22]. Indeed, GANT61 
has become the reference compound for CSC-tar-
geted therapies as it proved to inhibit the Hh pathway 
at Gli level in several cancer cells, CSCs and tumor 
animal models, such as pancreatic [17], prostate [14], 
lung [12], colon and hepatocellular cancer [50,51], as well 
as in tumors for which the role of Gli was not eluci-
dated before, including ovarian cancer [52], esopha-
geal adenocarcinoma and melanoma [8,53]. However, 
GANT61 inhibits Gli-mediated transcription by an 
unclear mechanism – most likely by inducing post-
translational modifications of Gli – with a reported 
IC
50
 of 5 μM (in HEK293 cell line). In our study, 
GlaB and NC-GlaB were shown to be more effective 
than GANT61 in inducing tumor cell death, with IC
50
 
 values in PANC1 of 1.62 and 1.49 μM, respectively.
Following up the positive in vitro studies, it was 
necessary to overcome the poor water solubility and 
bioavailability of GlaB so that it can be validated for 
clinical application. Our previous studies assessed 
organ distribution of PEG–NCs in a leaky solid tumor 
model – CT26 colon cancer – and approximately 0.8% 
ID/g of tissue in tumors was achieved 24 h postinjec-
tion [28]. Furthermore, curcumin, used as an antican-
cer drug in that study, has shown to be delivered to the 
tumor at therapeutic concentrations leading to signifi-
cant tumor growth delay [28]. In preparation for pre-
clinical testing of therapeutic activity, we first assessed 
organ biodistribution in PANC1-tumor-bearing mice. 
This tumor model is known to be highly resistant 
and not sufficiently leaky [17]. Such data will give us 
some guidance on the next stages required to prepare 
glioma-targeting NC formulation to deliver GlaB to 
brain cancer. Our results have shown that values of 
0.5–1.25% ID/g tissues were achieved in tumors 24 h 
postinjection. Taking into account the fact that the 
dose administered was approximately 370 μg GlaB 
per mouse, one would expect that drug concentra-
tions in the tumor to be approximately 1.9–4.4 μg/g 
tumor (4–10 nM). These concentrations are below the 
therapeutic concentrations used in PANC1, and it is 
therefore suggested that higher or multiple doses of the 
formulation is required.
The results obtained from this work gave us some 
guidance on the next stages, to use NCs in a leaky 
tumor. We are also currently working on reducing the 
size of our NCs to less than 150 nm as smaller sizes 
are expected to have better extravasation than 200 nm 
NCs, before testing them in other tumor models for 
therapy. Moreover, the therapeutic efficacy of these 
NCs will be tested against CSCs isolated from other 
types of tumor, such as pancreas, or Hh-driven tumors 
such as MB.
Conclusion
The efficient encapsulation of GlaB into oil-cored 
NCs (NC-GlaB) greatly improved the bioavailability 
and potential clinical application of this drug. More 
importantly, NC-GlaB retained the same antitumoral 
activity of the free drug, both revealing remarkable 
cell killing activity against Hh-dependent CSC lines 
and, to a lesser extent, non-stem cancer cells. Substan-
tial evidence is provided for a nanoparticle-based drug 
with good circulation profile that could be useful as 
part of a multimodal treatment for patients affected by 
Hh-dependent CSC-driven tumors.
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Executive summary
Background
•	 Use of PEG-conjugated polymeric oil-cored nanocapsules (NCs) to enhance systemic delivery of glabrescione B 
(GlaB).
Synthesis of GlaB
•	 The total synthesis of GlaB in six steps with an overall yield of 7% is reported for the first time.
Physico-chemical characterization of NCs
•	 GlaB was successfully loaded into NCs composed of castor-oil-cored NCs offering approximately 70-fold 
increase in GlaB aqueous solubility.
•	 Hydrodynamic diameter, polydispersity index, ζ potential and stability were determined.
•	 In vitro serum stability data suggest that there will be minimal drug release from the NC in blood circulation 
and that most of the drug will be released at the target site, in other words, the tumor.
In vitro functional assays
•	 Cell viability, cell cycle analysis and western blotting confirmed that cancer stem cell lines (G7, IENS) were more 
sensitive to GlaB than non-stem cancer cells (GL261, PANC1 and SKOV3).
•	 Differentiated G7 cells were drug insensitive as they could be less dependent on Hh pathway.
In vivo biodistribution
•	 The biodistribution of radiolabeled NC-GlaB was investigated in pancreatic-tumor-bearing SCID/Beige mice 
and 0.5–1.25% ID/g tissues were achieved in tumors at 24 h postinjection.
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